Cedar Creek tracks DeepIntent’s borrowing with SLR Investment to estimate Propel Media’s growth. Dividend delay noted. Read ...

The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Prucalopride Tablets, 1 mg and 2 mg (USRLD: Motegrity Tablets, 1 mg and 2 mg).

GLP-1 weight-loss drugs are popular but pricey. New data highlights use by age and gender - and why interest outpaces access for many.

Ahmedabad: Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for ZDS-Varenicline tablets ...

Pipeline Regulatory Progress -- Two risk-adjusted product launches (AMP-002 and AMP-015) are included in the flat full-year ...

Shares of Gartner Inc. slipped 5.75% to $229.69 Thursday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index falling 0.08% to 6,340.00 and Dow Jones ...

Pharmexcil Chairman warns US tariffs on Indian pharma will impact global industry, affecting affordable healthcare and ...

Meitheal appointed Keith Robinson as chief medical officer; Lonnie Brent was appointed senior vice president of medical ...

Zydus Lifesciences on Thursday said it has received a no objection certificate (NOC) from Health Canada for a product used to help quit smoking.